Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | ENPP1 | P22413 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | PDE2A | O00408 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4817006 | 0.99 | ALDH1A1 (0.37) | ALDH1A1ENPP1KMT2APOLBTSHR | |
| SCHEMBL6997181 | 0.97 | ALDH1A1 (0.38) | ALDH1A1ENPP1KMT2APOLBTSHR | |
| SCHEMBL6995491 | 0.92 | ALDH1A1 (0.40) | ALDH1A1ENPP1KMT2APOLBTSHR | |
| SCHEMBL4810488 | 0.91 | ALDH1A1 (0.38) | ALDH1A1ENPP1KMT2APOLBTSHR | |
| SCHEMBL6998016 | 0.88 | ALDH1A1 (0.41) | ALDH1A1ENPP1KMT2APOLBTSHR | |
| SCHEMBL4820443 | 0.84 | ALDH1A1 (0.39) | ALDH1A1ENPP1KMT2APOLBTSHR | |
| SCHEMBL4819336 | 0.83 | MBOAT4 (0.36) | ALDH1A1ENPP1KMT2APOLBTSHR | |
| SCHEMBL7957250 | 0.83 | ATM (0.43) | ALDH1A1ENPP1KMT2APOLBTSHR | |
| SCHEMBL4818702 | 0.83 | ALDH1A1 (0.39) | ALDH1A1ENPP1KMT2APOLBTSHR | |
| SCHEMBL4818695 | 0.82 | ALDH1A1 (0.39) | ALDH1A1ENPP1KMT2APOLBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1054888-B1 | FUNGICIDAL 7-ALKYL-TRIAZOLOPYRIMIDINES | BASF AG (DE) | 2003-11-26 | — | — | EP | claimed |
| US-20020068744-A1 | Substituted-triazolopyrimidines as anticancer agents | AMERICAN HOME PRODUCTS CORPORATION | 2002-06-06 | — | — | US | claimed |
| EP-1054888-A1 | FUNGICIDAL 7-ALKYL-TRIAZOLOPYRIMIDINES | AMERICAN CYANAMID COMPANY (US) | 2000-11-29 | — | — | EP | claimed |
| US-6020338-A | Fungicidal 7-alkyl-triazolopyrimidines | AMERICAN CYANAMID COMPANY (US) | 2000-02-01 | — | — | US | claimed |
| WO-1999041255-A1 | FUNGICIDAL 7-ALKYL-TRIAZOLOPYRIMIDINES | AMERICAN CYANAMID COMPANY (US) | 1999-08-19 | — | — | WO | claimed |
| US-7329663-B2 | Substituted-triazolopyrimidines as anticancer agents | WYETH (US) | 2008-02-12 | — | — | US | disclosed |
| EP-1054888-B1 | FUNGICIDAL 7-ALKYL-TRIAZOLOPYRIMIDINES | BASF AG (DE) | 2003-11-26 | — | — | EP | disclosed |
| EP-1359150-A2 | A process and intermediates for the preparation of fungicidal 7-alkyl-triazolopyrimidines | BASF AKTIENGESELLSCHAFT (DE) | 2003-11-05 | — | — | EP | disclosed |
| EP-1307200-A2 | SUBSTITUTED-TRIAZOLOPYRIMIDINES AS ANTICANCER AGENTS | Wyeth (US) | 2003-05-07 | — | — | EP | disclosed |
| US-20020068744-A1 | Substituted-triazolopyrimidines as anticancer agents | AMERICAN HOME PRODUCTS CORPORATION | 2002-06-06 | — | — | US | disclosed |
| WO-2002002563-A2 | SUBSTITUTED-TRIAZOLOPYRIMIDINES AS ANTICANCER AGENTS | WYETH (US) | 2002-01-10 | — | — | WO | disclosed |
| EP-1054888-A1 | FUNGICIDAL 7-ALKYL-TRIAZOLOPYRIMIDINES | AMERICAN CYANAMID COMPANY (US) | 2000-11-29 | — | — | EP | disclosed |
| US-6020338-A | Fungicidal 7-alkyl-triazolopyrimidines | AMERICAN CYANAMID COMPANY (US) | 2000-02-01 | — | — | US | disclosed |
| WO-1999041255-A1 | FUNGICIDAL 7-ALKYL-TRIAZOLOPYRIMIDINES | AMERICAN CYANAMID COMPANY (US) | 1999-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068744-A1 | Substituted-triazolopyrimidines as anticancer agents | TUBB3, TUBA1C, TUBB1 | ALDH1A1 2231/4885ENPP1 1402/4885KMT2A 2012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.